Christopher Haddad1*, Yasuo Kubota, MD, PhD2*, Carlos Bravo-Perez, MD, PhD2,3*, Carmelo Gurnari, MD2,4, Luca Guarnera, MD2,4*, Olisaemeka Ogbue2, Arda Durmaz, PhD2*, Ishani Nautiyal, BS2*, Aashray Mandala, BS2*, David S. Bosler, MD5*, Hetty E. Carraway, MD, MBA6, Yogen Saunthararajah, MD2, Valeria Visconte, PhD2 and Jaroslaw P. Maciejewski, M.D., Ph.D., FACP2
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Westlake, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain
4Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
5Pathology and Laboratory Medicine Institute (Robert J. Tomsich), Cleveland, OH
6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH